Lawrence Dubuske, MD
Allergy & Immunology · Washington, DCNPI 1649251778
Payments from drug & device makers
Across 2,095 payments — averaging $854.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$723K
- Sanofi$402K
- GSK$372K
- Regeneron Healthcare Solutions, Inc.$196K
- Alk-abello, Inc$46K
- Novartis$13K
- plus $37K from 21 others
What the payments were for
- Consulting fees$38,7882%
- Speaking & faculty fees$1,427,66480%
- Travel & lodging$281,67316%
- Food & beverage$40,9032%
- Education$2060%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 758 | $722,775 |
| Sanofi | 356 | $402,225 |
| GSK | 551 | $372,079 |
| Regeneron Healthcare Solutions, Inc. | 208 | $196,415 |
| Alk-abello, Inc | 66 | $46,039 |
| Novartis | 30 | $13,166 |
| Regeneron | 11 | $12,692 |
| Teva Pharmaceuticals USA, Inc. | 9 | $12,189 |
| Amgen(2 entities) | 50 | $9,512 |
| Optinose US, Inc. | 5 | $947 |
| Pfizer | 5 | $278 |
| Pharming Healthcare, Inc. | 14 | $234 |
| CSL Behring | 6 | $153 |
| Genentech USA, Inc. | 7 | $124 |
| Ionis Pharmaceuticals, Inc. | 2 | $58 |
| Grifols USA, LLC | 2 | $56 |
| Kaleo, Inc. | 2 | $41 |
| Phadia US Inc. | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Hikma Pharmaceuticals USA | 2 | $34 |
| Verona Pharma, Inc. | 1 | $28 |
| Lilly USA, LLC | 1 | $28 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $22 |
| LEO Pharma Inc. | 1 | $19 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$563,472
- FASENRA$524,368
- TRELEGY ELLIPTA$135,612
- TEZSPIRE$123,836
- NUCALA$103,398
- AIRSUPRA$71,606
- AREXVY$69,333
- Odactra$39,574
- ArmonAir Digihaler$12,151
- AirDuo RespiClick$12,151
- ProAir Digihaler$12,151
- XOLAIR$9,919
- Ragwitek$3,403
- Grastek$3,403
- Xhance$800
- Otiprio$450
- BREZTRI$249
- EUCRISA$235
- SYMBICORT$118
How this compares
$1,789,252 in reported general payments places this provider in the 90th percentile of 20 allergy & immunology providers in District of Columbia.
See all allergy & immunology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 14 | $61,809 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $56,558 |
| NucalaMepolizumab | 11 | $45,059 |
| Spiriva RespimatTiotropium Bromide | 30 | $22,520 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $12,538 |
| Incruse ElliptaUmeclidinium Bromide | 23 | $9,177 |
| Arnuity ElliptaFluticasone Furoate | 23 | $5,989 |
| DuleraMometasone/Formoterol | 13 | $5,702 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $3,565 |
| Azelastine Hcl | 73 | $3,133 |
| Epinephrine | 17 | $2,524 |
| Wixela InhubFluticasone Propion/Salmeterol | 16 | $2,412 |
| Ipratropium Bromide | 70 | $1,977 |
| Famotidine | 66 | $1,765 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 64 | $1,694 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Incruse Ellipta, Arnuity Ellipta | $372,079 | $116,783118 claims |
| AstraZenecaBreztri Aerosphere | $722,775 | $12,53820 claims |
| MerckDulera | $15 | $5,70213 claims |
| Hikma Pharmaceuticals USAEpinephrine | $34 | $2,52417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 20 allergy & immunology providers in District of Columbia.
Other allergy & immunology in Washington
- Autumn BurnetteWashington$2.3M
- Limone CollinsWashington$188K
- Michael KellerWashington$84K
- Eliane Abou-JaoudeWashington$66K
- Daniel EinWashington$52K
- Olabunmi AgboolaWashington$13K
- Dan BrodyWashington$9K
- Maribel Mamonluk-ChuaWashington$7K
- Sebastian Ochoa GonzalezWashington$6K
- Janine van LanckerWashington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.